Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Asks Philippines High Court To Reconsider Imports Decision

This article was originally published in PharmAsia News

Executive Summary

GlaxoSmithKline Philippines asked the Philippines Supreme Court to reconsider a decision that had the effect of declaring there is no law safeguarding the country from imported drugs not registered with the government. GSK wants a new look at a recent Supreme Court ruling that the Universally Accessible Cheaper and Quality Medicines Act of 2008 allows anyone to import and use medicines without fear of being prosecuted under the Counterfeit Drugs Act, which it declared void. GSK Philippines said the court in effect nullified the Bureau of Food and Drugs as well as the counterfeit law, so it filed a motion for the court to reconsider the decision. GSK said it had a different reading of the Cheaper Medicines Act, one that says the safeguards are in place. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071883

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel